Market Overview

Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.

Share:

Magenta
Therapeutics
, a biotechnology company developing novel medicines to
bring the curative power of bone marrow transplant to more patients,
today announced that chief operating officer Bastiano Sanna, Ph.D., has
resigned from the Company, effective March 30, to pursue an opportunity
outside of Magenta. Dr. Sanna has agreed to assist Magenta in an
advisory capacity through the second quarter of 2018.

"All of us at Magenta thank Bastiano for his many important
contributions and leadership across the organization, and we all wish
him the best as he moves to the next stage in his career," said Jason
Gardner, D.Phil., chief executive officer, president and co-founder,
Magenta Therapeutics.

"I am proud of the tremendous progress Magenta has made since its launch
in late 2016. It has been an honor to help build the leading transplant
medicine company," said Dr. Sanna. "I've enjoyed having the opportunity
to work with this extraordinary team of world-class scientists, and I
look forward to following Magenta's continued success as it works to
transform the lives of patients."

About Bone Marrow Transplant
Healthy bone marrow stem cells
and the blood cells they create are crucial for survival, but certain
diseases can affect the bone marrow, interfering with its ability to
function properly. A bone marrow transplant is a process to replace
unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow
transplant can save the lives of patients with blood cancers and genetic
diseases and is a potential cure for patients with severe refractory
autoimmune diseases. Currently bone marrow transplant is still
associated with risk, toxic side effects, and complexity for patients
that could benefit from the procedure. Magenta is working to address
these challenges through its integrated portfolio of therapeutics.

About Magenta Therapeutics
Magenta Therapeutics is a
biotechnology company developing therapeutics to revolutionize bone
marrow transplant for patients with autoimmune diseases, blood cancers
and genetic diseases. By creating a platform focused on critical areas
of unmet need, Magenta Therapeutics is pioneering an integrated approach
to extend the curative power of bone marrow transplant to more patients,
by making the process more effective, safer, and easier. Founded by
internationally recognized leaders in bone marrow transplant medicine,
Magenta Therapeutics was launched in 2016 by Third Rock Ventures and
Atlas Venture and is headquartered in Cambridge, Mass. For more
information, please visit www.magentatx.com.

View Comments and Join the Discussion!